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Correction to some statements about aluminum in Sulaiman et al.
Robert A. Yokel, Ph.D.
Department of Pharmaceutical Sciences
College of Pharmacy
University of Kentucky Academic Medical Center
Lexington, KY, 40536-0596, US
e-mail: ryokel@uky.edu
I am addressing the following statements in Sulaiman R, Wang M, Ren X. 2020. Exposure to
aluminum, cadmium, and mercury and autism spectrum disorder in children: A systematic review and
meta-analysis. Chem. Res. Toxicol. Published ASAP, September 29, 2020.
• “Environmental levels of Al vary depending on location and weather, with industrial cities recording
air concentrations up to 3 mg/m3.” The cited reference 1 states: “In general, background levels of
aluminum in the atmosphere are low, typically ranging from about 0.005 to 0.18 μg/m3. Much higher
levels are routinely observed in urban and industrial locations. A mean aluminum concentration of
474.6 ng/m3 (range 38.4–2,619.6 ng/m3) was reported in particulate matter collected in air from
downtown Rio de Janeiro, Brazil.” 2,619.6 ng/m3 would round up to 3 μg/m3, not mg/m3.
• “The FDA has no limits on the amount of Al in foods or medicines”.
o There is a limit to the amount of aluminum in biologics, such as vaccines. The amount of
aluminum in the recommended individual dose of a biological product shall not exceed: (1)
0.85 milligrams if determined by assay; (2) 1.14 milligrams if determined by calculation on the
basis of the amount of aluminum compound added; or (3) 1.25 milligrams determined by
assay. 21CFR610.15
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=610.15
o There are limits to aluminum in large and small volume parenterals used in total parenteral
nutrition. The aluminum content of large volume parenteral (LVP) drug products used in total
parenteral nutrition (TPN) therapy must not exceed 25 micrograms per liter. … the maximum
level of aluminum present at expiry must be stated on the immediate container label of all
small volume parenteral (SVP) drug products and pharmacy bulk packages (PBPs) used in the
preparation of TPN solutions. 21CFR201.323
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=201.323
• “The body burden of Al is difficult to measure because most of it is stored in bone and the brain”.
Normal human tissue aluminum levels are 1.0, 1.2, 2.2, 2.6, 3.3, 4.1, and 43 mg/kg in heart, muscle,
brain gray matter, spleen, bone, liver, and lung 2. Based on organ weights, ~ 54% of aluminum is in
the skeleton and 1% in the central nervous system 3.
• “Al in blood binds to albumin”. Approximately 90% of aluminum in plasma is bound to transferrin.
Most of the remainder is bound to citrate 4,5.
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